NYSEARCA:PRME Prime Medicine - PRME Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $21.11 +1.11 (+5.55%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$19.73▼$21.4850-Day Range$15.85▼$21.1152-Week Range$14.52▼$21.73Volume439,993 shsAverage Volume152,800 shsMarket Capitalization$1.99 billionP/E RatioN/ADividend YieldN/APrice Target$23.75 ProfileChartInstitutional OwnershipHeadlines Receive PRME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prime Medicine and its competitors with MarketBeat's FREE daily newsletter. Email Address View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PRME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prime Medicine and its competitors with MarketBeat's FREE daily newsletter. Email Address Basic Details Issuer First Trust Fund NameFirst Trust Heitman Global Prime Real Estate ETF Tax ClassificationRegulated Investment Company SymbolNYSEARCA:PRME Inception Date11/12/2015 Fund ManagerJerry Ehlinger, John White, Jacques Perdrix, Andreas Welter Webwww.primemedicine.com PhoneN/AFund Focus Asset ClassReal Estate BenchmarkNot Applicable CategoryReal Estate FocusReal Estate Development LevelBlended Development RegionGlobal Fund Statistics Assets Under Management$1.03 million Average Daily Volume$213.00 Discount/Premium3.91% ETF Expenses Management Fee0.95% Other Expenses0.00% Total Expenses0.95% Fee Waiver0.00% Net Expenses0.95%Administrator, Advisor and Custodian AdministratorBrown Brothers Harriman & Co. AdvisorFirst Trust Advisors L.P. CustodianBrown Brothers Harriman & Co. DistributorFirst Trust Portfolios L.P. Transfer AgentBrown Brothers Harriman & Co. Trustee Lead Market MakerCredit Suisse Key ExecutivesDr. Keith Michael Gottesdiener M.D. (Age 69)Pres, CEO, Sec. & Director Comp: $867.11kDr. Ann L. Lee Ph.D. (Age 61)Chief Technical Officer Comp: $171.19kDr. Jeremy S. Duffield M.D. (Age 55)Ph.D., Chief Scientific Officer Comp: $994.4kDr. Andrew Anzalone M.D. (Age 37)Ph.D., Co-Founder, Sr. Scientist II, Head of Prime Editing Platform & Head of Platform Devel. Dr. David R. Liu Ph.D.Co-Founder & Chair of Scientific Advisory BoardMs. Carman Alenson CPA (Age 58)M.B.A., Chief Accounting Officer & Interim CFO Dr. Meredith Goldwasser (Age 52)Sr. VP of Strategy & Corp. Operations and Head of Strategy & Corp. Operations Dr. Karen Brown J.D.Ph.D., Sr. VP of Intellectual Property & Legal AffairsMs. Niamh AlixChief HR OfficerMr. Richard Brudnick (Age 65)Chief Bus. Officer More ExecutivesKey CompetitorsTwist BioscienceNASDAQ:TWSTRecursion PharmaceuticalsNASDAQ:RXRXImmunityBioNASDAQ:IBRXArcellxNASDAQ:ACLXReplimune GroupNASDAQ:REPLView All CompetitorsInsiders & InstitutionsOUP Management Co. LLCBought 121,255 shares on 2/2/2023Ownership: 0.129%Sumitomo Mitsui Trust Holdings Inc.Bought 488,226 shares on 1/30/2023Ownership: 0.518%New York State Common Retirement FundBought 5,000 shares on 1/30/2023Ownership: 0.005%Strs OhioBought 2,400 shares on 1/26/2023Ownership: 0.003%Clarius Group LLCBought 16,080 shares on 1/25/2023Ownership: 0.017%View All Insider TransactionsView All Institutional Transactions PRME Stock - Frequently Asked Questions Should I buy or sell Prime Medicine stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prime Medicine in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PRME shares. View PRME analyst ratings or view top-rated stocks. What is Prime Medicine's stock price forecast for 2023? 4 brokers have issued 12 month target prices for Prime Medicine's stock. Their PRME share price forecasts range from $21.00 to $27.00. On average, they predict the company's stock price to reach $23.75 in the next twelve months. This suggests a possible upside of 12.5% from the stock's current price. View analysts price targets for PRME or view top-rated stocks among Wall Street analysts. How have PRME shares performed in 2023? Prime Medicine's stock was trading at $18.58 at the start of the year. Since then, PRME stock has increased by 13.6% and is now trading at $21.11. View the best growth stocks for 2023 here. What is Prime Medicine's stock symbol? Prime Medicine trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "PRME." When does the company's lock-up period expire? Prime Medicine's lock-up period expires on Tuesday, April 18th. Prime Medicine had issued 10,294,118 shares in its public offering on October 20th. The total size of the offering was $175,000,006 based on an initial share price of $17.00. After the expiration of the company's lock-up period, company insiders and major shareholders will be able to sell their shares of the company. Who are Prime Medicine's major shareholders? Prime Medicine's stock is owned by a variety of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (1.74%), Sumitomo Mitsui Trust Holdings Inc. (0.52%), OUP Management Co. LLC (0.13%), Clarius Group LLC (0.02%), New York State Common Retirement Fund (0.01%) and Strs Ohio (0.00%). Insiders that own company stock include 2019 Gp LLC Gv and Thomas Cahill. View institutional ownership trends. How do I buy shares of Prime Medicine? Shares of PRME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Prime Medicine's stock price today? One share of PRME stock can currently be purchased for approximately $21.11. How much money does Prime Medicine make? Prime Medicine (NYSEARCA:PRME) has a market capitalization of $1.99 billion. This page (NYSEARCA:PRME) was last updated on 2/5/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.